SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001387131-22-001709
Filing Date
2022-02-11
Accepted
2022-02-11 17:09:04
Documents
2
Group Members
ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLCATLAS VENTURE ASSOCIATES X, L.P.ATLAS VENTURE ASSOCIATES X, LLCATLAS VENTURE OPPORTUNITY FUND I, L.P.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT TO SC 13G kymr-sc13ga_123121.htm SC 13G/A 100020
2 EXHIBIT A - JOINT FILING AGREEMENT ex-a.htm EX-1 14911
  Complete submission text file 0001387131-22-001709.txt   116740
Mailing Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Atlas Venture Fund X, L.P. (Filed by) CIK: 0001628098 (see all company filings)

IRS No.: 472435989 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472
Business Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Subject) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-91636 | Film No.: 22622579
SIC: 2836 Biological Products, (No Diagnostic Substances)